Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESENDO in Severe Coronary Ischemia
NCT00790764Phase 2Suspended
- Sponsor
- TCA Cellular Therapy
- Start
- Nov 2008
- Primary completion
- May 2014
- Modality
- Bone Marrow HSCs, Adipose-derived MSCs, Patient-derived iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of Mesendo in coronary ischemia, sponsored by TCA Cellular Therapy. Started Nov 2008; status: suspended.
02
Drugs
Mesendo
03
Conditions
coronary ischemia
Beyond the preview
Go deeper on NCT00790764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790764.